Skip to main content
Top
Published in: World Journal of Urology 4/2020

01-04-2020 | Aminoglycoside | Original Article

Quality improvement initiative to reduce variability and improve stewardship of antimicrobial prophylaxis for transrectal prostate needle biopsy

Authors: Pedro Recabal, Taehyoung Lee, Emily Vertosick, Michael Manasia, James Eastham, Karim Touijer, Susan K. Seo, Massimiliano Spaliviero, Behfar Ehdaie

Published in: World Journal of Urology | Issue 4/2020

Login to get access

Abstract

Purpose

To assess the impact of implementing the recommendations included in the 2014 American Urological Association (AUA) white paper on complications of transrectal prostate needle biopsy (PNB).

Methods

In the outpatient setting of a single tertiary-care institution, prophylactic antibiotic use and rate of infectious complications were compared before and after implementation by nursing of a standardized algorithm to select antibiotic prophylaxis (derived from the recommendations of the AUA white paper). The 584 patients in cohort A (January 2011–January 2012) received antimicrobial prophylaxis at the discretion of the treating physician; 654 patients in cohort B (January 2014–January 2015) received standardized risk-adapted antibiotic prophylaxis. Data on antibiotics administered and infectious complications were analyzed.

Results

Fluoroquinolone was the most common prophylactic regimen in both cohorts. In cohort A, 73% of men received a single-drug regimen, although 19 different regimens were utilized with duration of 72 h. In cohort B, 97% received 1 of 4 standardized single-drug antibiotic regimens for duration of 24 h. Infectious complications occurred in 19 men (3.3%) in cohort A, and in 18 men (2.8%) in cohort B (difference − 0.5%; one-sided 95% CI 1.1%). No clinically relevant increase in infectious complication rates was found after implementing this quality improvement initiative.

Conclusions

Use of a standardized risk-adapted approach to select antibiotic prophylaxis for PNB by nursing staff reduced the duration of antimicrobial prophylaxis and number of antibiotic regimens used, without increasing the rate of infectious complications. Our findings validate the current AUA recommendations for antibiotic prophylaxis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186(5):1830–1834CrossRef Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186(5):1830–1834CrossRef
2.
go back to reference Zani EL, Clark OAC, Rodrigues Netto N Jr (2011) Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 11(5):CD006576 Zani EL, Clark OAC, Rodrigues Netto N Jr (2011) Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 11(5):CD006576
3.
go back to reference Yang L, Gao L, Chen Y et al (2015) Prophylactic antibiotics in prostate biopsy: a meta-analysis based on randomized controlled trials. Surg Infect (Larchmt) 16(6):733–747CrossRef Yang L, Gao L, Chen Y et al (2015) Prophylactic antibiotics in prostate biopsy: a meta-analysis based on randomized controlled trials. Surg Infect (Larchmt) 16(6):733–747CrossRef
4.
go back to reference Kapoor DA, Klimberg IW, Malek GH et al (1998) Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 52(4):552–558CrossRef Kapoor DA, Klimberg IW, Malek GH et al (1998) Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 52(4):552–558CrossRef
5.
go back to reference Feliciano J, Teper E, Ferrandino M et al (2008) The incidence of fluoroquinolone resistant infections after prostate biopsy—are fluoroquinolones still effective prophylaxis? J Urol 179(3):952–955CrossRef Feliciano J, Teper E, Ferrandino M et al (2008) The incidence of fluoroquinolone resistant infections after prostate biopsy—are fluoroquinolones still effective prophylaxis? J Urol 179(3):952–955CrossRef
6.
go back to reference Wagenlehner FM, van Oostrum E, Tenke P et al (2013) Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 63(3):521–527CrossRef Wagenlehner FM, van Oostrum E, Tenke P et al (2013) Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 63(3):521–527CrossRef
7.
go back to reference Nam RK, Saskin R, Lee Y et al (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183(3):963–968CrossRef Nam RK, Saskin R, Lee Y et al (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183(3):963–968CrossRef
8.
go back to reference Liss MA, Chang A, Santos R et al (2011) Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 185(4):1283–1288CrossRef Liss MA, Chang A, Santos R et al (2011) Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 185(4):1283–1288CrossRef
9.
go back to reference Marino K, Parlee A, Orlando R, Lerner L, Strymish J, Gupta K (2015) Comparative effectiveness of single versus combination antibiotic prophylaxis for infections after transrectal prostate biopsy. Antimicrob Agents Chemother 59(12):7273–7275CrossRef Marino K, Parlee A, Orlando R, Lerner L, Strymish J, Gupta K (2015) Comparative effectiveness of single versus combination antibiotic prophylaxis for infections after transrectal prostate biopsy. Antimicrob Agents Chemother 59(12):7273–7275CrossRef
10.
go back to reference Averch T, Tessier C, Clemens JQ et al (2015) AUA Quality Improvement Summit 2014: conference proceedings on infectious complications of transrectal prostate needle biopsy. Urol Pract 2(4):172–180CrossRef Averch T, Tessier C, Clemens JQ et al (2015) AUA Quality Improvement Summit 2014: conference proceedings on infectious complications of transrectal prostate needle biopsy. Urol Pract 2(4):172–180CrossRef
11.
go back to reference Ehdaie B, Vertosick E, Spaliviero M et al (2014) The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 191(3):660–664CrossRef Ehdaie B, Vertosick E, Spaliviero M et al (2014) The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 191(3):660–664CrossRef
12.
go back to reference Aron M, Rajeev TP, Gupta NP (2000) Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 85(6):682–685CrossRef Aron M, Rajeev TP, Gupta NP (2000) Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 85(6):682–685CrossRef
13.
go back to reference Petteffi L, Toniazzo GP, Sander GB, Stein AC, Koff WJ (2002) Efficiency of short and long term antimicrobial therapy in transrectal ultrasound-guided prostate biopsies. Int Braz J Urol 28(6):526–532PubMed Petteffi L, Toniazzo GP, Sander GB, Stein AC, Koff WJ (2002) Efficiency of short and long term antimicrobial therapy in transrectal ultrasound-guided prostate biopsies. Int Braz J Urol 28(6):526–532PubMed
14.
go back to reference Schaeffer AJ, Montorsi F, Scattoni V et al (2007) Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU Int 100(1):51–57CrossRef Schaeffer AJ, Montorsi F, Scattoni V et al (2007) Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU Int 100(1):51–57CrossRef
15.
go back to reference Cam K, Kayikci A, Akman Y, Erol A (2008) Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy. Int J Urol 15(11):997–1001CrossRef Cam K, Kayikci A, Akman Y, Erol A (2008) Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy. Int J Urol 15(11):997–1001CrossRef
16.
go back to reference Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL (2013) Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis 57(2):267–274CrossRef Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL (2013) Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis 57(2):267–274CrossRef
17.
go back to reference Toner L, Bolton DM, Lawrentschuk N (2016) Prevention of sepsis prior to prostate biopsy. Investig Clin Urol 57(2):94–99CrossRef Toner L, Bolton DM, Lawrentschuk N (2016) Prevention of sepsis prior to prostate biopsy. Investig Clin Urol 57(2):94–99CrossRef
18.
go back to reference Iwamoto H, Shigehara K, Miyagi T, Nakashima T, Shimamura M, Namiki M (2015) Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate. Prostate Int 3(3):103–106CrossRef Iwamoto H, Shigehara K, Miyagi T, Nakashima T, Shimamura M, Namiki M (2015) Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate. Prostate Int 3(3):103–106CrossRef
19.
go back to reference Cussans A, Somani BK, Basarab A, Dudderidge TJ (2016) The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review. BJU Int 117(5):725–731CrossRef Cussans A, Somani BK, Basarab A, Dudderidge TJ (2016) The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review. BJU Int 117(5):725–731CrossRef
20.
go back to reference Liss MA, Kim W, Moskowitz D, Szabo RJ (2015) Comparative effectiveness of targeted vs empirical antibiotic prophylaxis to prevent sepsis from transrectal prostate biopsy: a retrospective analysis. J Urol 194(2):397–402CrossRef Liss MA, Kim W, Moskowitz D, Szabo RJ (2015) Comparative effectiveness of targeted vs empirical antibiotic prophylaxis to prevent sepsis from transrectal prostate biopsy: a retrospective analysis. J Urol 194(2):397–402CrossRef
21.
go back to reference Li CK, Tong BC, You JH (2016) Cost-effectiveness of culture-guided antimicrobial prophylaxis for the prevention of infections after prostate biopsy. Int J Infect Dis 43:7–12CrossRef Li CK, Tong BC, You JH (2016) Cost-effectiveness of culture-guided antimicrobial prophylaxis for the prevention of infections after prostate biopsy. Int J Infect Dis 43:7–12CrossRef
Metadata
Title
Quality improvement initiative to reduce variability and improve stewardship of antimicrobial prophylaxis for transrectal prostate needle biopsy
Authors
Pedro Recabal
Taehyoung Lee
Emily Vertosick
Michael Manasia
James Eastham
Karim Touijer
Susan K. Seo
Massimiliano Spaliviero
Behfar Ehdaie
Publication date
01-04-2020
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 4/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02845-0

Other articles of this Issue 4/2020

World Journal of Urology 4/2020 Go to the issue